Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab in Hospitalized Patients With Acute COVID-19
NCT04432298Phase 2Terminated
- Sponsor
- FibroGen
- Start
- Jun 2020
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pamrevlumab in coronavirus disease 2019 (COVID-19), sponsored by FibroGen. Started Jun 2020; status: terminated.
02
Drugs
pamrevlumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04432298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04432298.